Peroxisome proliferator-activated receptor-g coactivators PGC1a and PGC1b modulate mitochondrial biogenesis and energy homeostasis. The function of these transcriptional coactivators is impaired in obesity, insulin resistance, and type 2 diabetes. We searched for transcriptomic, lipidomic, and electrophysiological alterations in PGC1b 2/2 hearts potentially associated with increased arrhythmic risk in metabolic diseases.
Introduction
Increasing evidence implicates the metabolic conditions of obesity, insulin resistance, and type 2 diabetes as risk factors for arrhythmia. This could manifest as QT prolongation, 1 T wave alternans, 2 atrial fibrillation, 3 and ventricular arrhythmia, 4 potentially leading to sudden cardiac death. 5 In addition, the accompanying cardiac ischaemia, myopathy, hypertrophy, or failure are themselves associated with cardiac arrhythmia. All three metabolic conditions are associated with an impaired mitochondrial oxidative capacity, 6, 7 which is in turn regulated by several transcriptional coactivators that include the peroxisome proliferator-activated receptor-g coactivators PGC1a and PGC1b.
PGC1a and PGC1b modulate mitochondrial biogenesis and energy homeostasis through their coordinated coactivation of metabolically relevant transcription factors, such as PPARa, PPARg, estrogenrelated receptor a, and nuclear respiratory factor 1. 8, 9 PGCs are highly expressed in oxidative tissues, including heart, skeletal muscle, and brown adipose tissue. 9 Decreased PGC1a and PGC1b expression are associated with obesity, insulin resistance, and type 2 diabetes, 10 -14 and first-degree relatives of diabetic patients, 15 consistent with a role in the pathogenesis of the metabolic syndrome. Genetic ablation of PGC1a and/or PGC1b reduces perinatal survival 16 -18 in mice in the absence of either cellular or anatomical cardiac abnormalities. Murine pups with deletions in both PGC1a and PGC1b (PGC1ab 2/2 ) die before weaning, possibly from cardiac failure accompanied by atrioventricular block. 18 Defects in PGC1a and/or PGCb may thus have a primary role in determining cardiac morbidity and mortality in metabolic disorders. Of these two variants, PGC1a has already been studied extensively and has been implicated in cardiac hypertrophy and failure. 19, 20 In contrast, relatively few studies have searched for possible roles of PGC1b in cardiac physiology. Our previous study had shown a mild cardiac phenotype of impaired chronotropic responses to adrenergic stress, 21 but a subsequent study showed significantly reduced survival rates in PGC1b 2/2 mice. 18 This directly prompted us to investigate possible relationships between PGC1b and arrhythmic phenotypes.
The present experiments explored metabolic and possible arrhythmic phenotypes resulting from the PGC1b deletion. 21 They then investigated cellular, electrophysiological, and Ca 2+ homeostatic changes that might relate to these findings in the process of characterizing this experimental system for the first time.
Methods
The Supplementary materials online contain further details.
2.1 Generation of PGC1b 2/2 mice PGC1b 2/2 mice were generated using a triple LoxP targeting vector as described previously. 21 In brief, the targeting vector containing a floxed neomycin phosphotransferase selectable marker cassette inserted into intron 3 and a single LoxP site inserted into intron 5, resulting in deletion of exons 4 and 5. Southern blots confirmed the presence of three LoxP sites in embryonic stem cells. Heterozygous triple LoxP mice crossed with ROSA26-Cre mice generated heterozygous PGC1b mice, which were further bred to generate homozygous PGC1b 2/2 mice. Animal protocols and procedures used in this study were approved by the UK Home 
Histology
Picrosirius staining 22 and Oil Red O Staining 23 were performed on hearts from 12-week-old mice as described previously. 21 There were no differences between PGC1b 2/2 and WT mice in heart:body weight ratios, cardiac morphology, and degree of hypertrophy, interstitial fibrosis, and lipid accumulation (Supplementary material online, Figure S1A -C, respectively).
RNA preparation and real-time quantitative RT-PCR
Cardiac samples from 12-week-old male mice were extracted for RNA and purified using the RNA clean-up protocol from the RNeasy Mini Kit (Qiagen Ltd, Crawley, UK). Supplementary material online, Table S1 summarizes primer and probe sequences, together with gene abbreviations.
RNA amplification and hybridization
This used the Affymetrix GeneChip w Mouse Genome 430 2.0 array (Affymetrix, Santa Clara, CA, USA). For each sample, 4 mg of total RNA was amplified and labelled using the Affymetrix One-Cycle Target Labelling kit (Affymetrix). The amplified targets were hybridized to the array following the manufacturer's protocol (Affymetrix) and scanned using a Gen-eChip Scanner 3000 7G. CEL files were extracted from the image files automatically by Affymetrix GeneChip Operating Software (GCOS).
Microarray data analysis
Microarray gene expression analysis used GeneSpring GX 11.0.2 software (Agilent Technologies Inc., Santa Clara, CA, USA). Genes showing 1.5-fold changes in expression level are listed in Supplementary material online, Table S2 . Supplementary material online, Table S3 lists the canonical pathways, showing the ratios and the P-values. Supplementary material online, Table S4 lists the most significantly altered networks identified. Gene set enrichment analysis is listed in Supplementary material online, Table S5 .
Lipid profiling
Lipid extracts from mouse hearts, prepared as described previously, 24 were analyzed on a Q-ToF Premier mass spectrometer combined with an Acquity Ultra Performance Liquid chromatography (UPLC/MS) (Waters, Inc., Elstree, Hertfordshire, UK). Mass spectrometry was carried out on Q-Tof Premier (Waters, Inc.) run in ESI+ mode. The data were collected over the mass range of m/z 300 -1200 with a scan duration of 0.2 s as described previously. 24 The obtained data were converted into netCDF file format using Dbridge software from MassLynx (Waters, Inc.). The converted data were processed using MZmine software version 0.60. 25 Lipids were identified based on their retention time (RT) and mass to charge ratio (m/z) using our in-house-built lipid database as previously described. 24 
In vivo electrocardiography (ECG) and pharmacological studies
Lead I ECGs were recorded in mice anaesthetized with intraperitoneal ketamine and xylazine (150 and 5 mg/kg, respectively), and compared before and 10 min following intraperitoneal isoprenaline (2 mg/kg) injection.
Arrhythmogenic assessment
in Langendorff-perfused hearts 7.4 by bubbling with 95% O 2 and 5% CO 2 ). Programmed electrical stimulation (PES) assessed ventricular arrhythmogenicity during monophasic action potential (MAP) recording. 24 PES consisted of eight regularly paced stimuli (S 1 , 8 Hz) followed by an extrasystolic stimulus (S 2 ). With each successive cycle, the interval between the 8th S 1 and S 2 stimuli was reduced by 1 ms until the S 2 stimulus either failed to generate an AP or induced ventricular tachycardia (VT).
Ventricular myocyte isolation and Ca 21 imaging
Ventricular myocytes were isolated by enzymatic digestion (collagenase type II and hyaluronidase) of mouse hearts as detailed in Gurung et al. 26 Myocytes were incubated with 10 mM fluo-4 AM for 30 min. Fluo-4loaded ventricular myocytes were electrically excited, and fluorescence was recorded in line-scan mode using a Leica confocal microscope. 26 The Ca 2+ transients were expressed as peak values (F) normalized to baseline fluorescence (F 0 ). Isoprenaline (10 nM) was applied through a gravity-driven perfusion system (3 mL/min).
Whole-cell patch-clamp experiments
The external saline contained (mM): 145 NaCl, 5 KCl, 1 CaCl 2 , 1 MgCl 2 , 10 glucose, 10 Hepes; pH adjusted to 7.4 with NaOH. Experiments were carried out at 378C. For Ca 2+ current measurements, the pipette solution contained (mM): 57.26 CsCl, 52.74 caesium aspartate, 5 Na 2 -ATP, 5.37 MgCl 2 , 10 Hepes, 5 Cs 4 -BAPTA; pH adjusted to 7.2 with CsOH. For action potential (AP) measurements, the pipette solution contained (mM): 115 potassium aspartate, 5 KCl, 10 NaCl, 10 Hepes, 5 Mg-ATP, 5 BAPTA; pH adjusted to 7.2 with KOH. APs were induced in current-clamped ventricular myocytes using 2-ms-long depolarizing, 500 -1000 pA currents. Electrophysiological recordings were made in voltage-and current-clamp modes of a Multiclamp 700B (Molecular Devices, Sunnyvale, CA, USA).
Results

Lipidomic and transcriptomic changes suggest a pro-arrhythmogenic phenotype in PGC1b 2/2 mice
To identify cardiac phenotypes, we performed transcriptomic and lipidomic analyses of myocardial tissue. Supplementary material online, Table S2 lists genes showing .1.5-fold changes in expression levels in PGC1b 2/2 compared with wild-type (WT) hearts in microarray data analysis. The major genes with increased expression included AQP6, HSPA1B, PTTG1, HSPA1A, ACTA1, and TNNI2. Genes with decreased expression included NDRG4, BDH1, SLC41A3, UQCC, and NDUFA10. Several genes related to cardiac hypertrophy (ATF3, IFRD1, TNNT1, TNNI2, ACTA1, NEB, MYL1, and MAP3K6), hypoxia and heart failure (FKPB5, ZBTB16, SERPINE1, CTGF, TSC22D3, KLF2, HSPA1A, and HSPA1B), and cAMP and b-adrenergic signalling cascades (ATF3, PDE7, and CAMK2D) were also up-regulated. Furthermore, ingenuity pathway analysis (IPA) showed that canonical pathways involving Ca 2+ signalling, glucocorticoid receptor signalling, ubiquinone biosynthesis, and mitochondrial dysfunction were affected (Supplementary material online, Table S3 ). In the genetic network analysis, IPA also indicated that genes involved in cell death and proliferation, cell signalling, and lipid metabolism were particularly affected (Supplementary material online, Table S4 ). Gene set enrichment analysis of microarray data revealed that the significantly enriched gene sets (P , 0.0001, q , 0.0001) concerned the electron transport chain, oxidative-phosphorylation-related pathways, the Krebs cycle, and several other metabolic pathways. These pathways contain genes down-regulated in PGC1b 2/2 . In addition, gene sets involved in heart failure, striated muscle contraction, and circadian exercise showed significant up-regulation in PGC1b 2/2 (Supplementary material online, Table S5 ). Several genes (CASQ1, PDE7A, CAMK2D, and SCN4B) known to be involved in cardiac electrophysiology and Ca 2+ handling were also up-regulated. Overall, transcriptomic data analysis indicated a potential cardiac stress, metabolic impairment, and electrophysiological problems, despite apparently normal PGC1b 2/2 cardiac function.
As lipids constitute a major fuel in cardiac cells, down-regulation of the electron transport chain and oxidative phosphorylation might well affect myocardial lipid metabolism. 27 Thus, lipidomics analysis associated specific changes in cardiac lipid composition with PGC1b 2/2 ( Figure 1A -D). PGC1b 2/2 hearts had similar levels of phospholipids (PL; Figure 1A ), but decreased accumulation of triacylglycerols (TAG; Figure 1A ) compared with WT. Ceramide levels were not altered ( Figure 1B ), but ceramide:TAG ratios increased (P , 0.05; Figure 1C ). The most metabolically relevant data were increases in lysophophatidylcholines [lysoPC (18:2), lysoPC(20:4), lysoPC(18:2e), and lysoPC(16:1e)] in PGC1b 2/2 (P , 0.05; Figure 1D ). Levels of these lipotoxic metabolites are known to be increased in experimentally induced severe cardiac hypoxia and ischaemia, 28, 29 overt diabetes, and advanced atherosclerosis. 30 Accumulation of lysophosphatidylcholine-related lipid metabolites is known to cause arrhythmia during cardiac ischaemia and cardiac hypoxia, 28, 29 and to induce lipotoxicity and inflammation in obesity and diabetes. 30 This accumulation of pro-inflammatory and pro-arrhythmic metabolites prompted us to investigate potential arrhythmogenic phenotypes in PGC1b 2/2 .
Arrhythmogenic characteristics of PGC1b 2/2 hearts
In vivo ECG measurements in anaesthetized PGC1b 2/2 mice revealed several electrophysiological abnormalities. Two of five PGC1b 2/2 mice showed irregular PR, PP and RR intervals (Figure 2A and C), with frequent alterations in P wave morphology. This indicated multiple sites of origin of sinus rhythm, the existence of atrial ectopic beats, and atrioventricular block. Intraperitoneal isoprenaline (2 mg/kg) injection induced prompt increases in heart rate (HR) in both WT and PGC1b 2/2 mice ( Figure 2D ). PGC1b 2/2 mice showed more gradual and biphasic increases in HR, which rapidly declined to baseline, compared with WT ( Figure 2D ). Furthermore, two of five PGC1b 2/2 , but not WT hearts (n ¼ 5), showed polymorphic ventricular tachycardia (PVT) after 10 min of isoprenaline infusion ( Figure 2B ), suggesting increased susceptibility to catecholamine-induced ventricular arrhythmia.
Consistent with the arrhythmia observed in vivo, PES in Langendorff-perfused hearts also induced ventricular tachycardia in nine of 10 PGC1b 2/2 ( Figure 2F ) compared with only one of nine WT hearts. MAP durations measured in regularly paced (8 Hz) Langendorff-perfused hearts were indistinguishable between PGC1b 2/2 and WT hearts [action potential duration values at 90% full repolarization (APD 90 ): 41 + 4 ms, n ¼ 9, in WT vs. 42 + 4 ms, n ¼ 10, in PGC1b 2/2 ; P . 0.05]. However, MAPs recorded from two of 10 PGC1b 2/2 hearts showed duration alternans, as well as early after-depolarizations (EADs; Figure 2E ). This demonstrates increased arrhythmic susceptibility in PGC1b 2/2 hearts even in the absence of adrenergic stress attributable to increased arrhythmogenic substrate.
Abnormal Ca 21 homeostasis in PGC1b 2/2 myocytes
Abnormal Ca 2+ homeostasis manifesting as elevated diastolic Ca 2+ concentrations, and diastolic Ca 2+ transients causes arrhythmia in ischaemic heart disease, heart failure, diabetic cardiomyopathy, 31, 32 and catecholaminergic polymorphic ventricular tachycardia (CPVT). We looked for an involvement of abnormal Ca 2+ homeostasis in ventricular myocytes in isoprenaline-induced arrhythmias in PGC1b 2/2 mice. Regularly stimulated WT myocytes (n ¼ 24) showed regular Ca 2+ transients with stable diastolic Ca 2+ levels ( Figure 3A) . Application of 10 nM isoprenaline increased the amplitude of Ca 2+ transients without evidence for increases in diastolic Ca 2+ ( Figure 3A , lower panel, n ¼ 24). In contrast, most (70%) myocytes from PGC1b 2/2 hearts showed Ca 2+ transients with elevated diastolic Ca 2+ levels and frequent increases in diastolic Ca 2+ transients between consecutive evoked Ca 2+ transients ( Figure 3C, n ¼ 24) . Some of these diastolic Ca 2+ transients became Ca 2+ waves, producing temporal and spatial Ca 2+ heterogeneities ( Figure 3C) . The amplitude and frequency of these diastolic Ca 2+ transients increased with the addition of 10 nM isoprenaline. Approximately 30% of PGC1b 2/2 myocytes exhibited regular Ca 2+ transients in control conditions and diastolic Ca 2+ increases when exposed to 10 nM isoprenaline ( Figure 3B, n ¼  10) . Accordingly, a significantly greater proportion of the PGC1b 2/2 myocytes showed diastolic Ca 2+ transients ( Figure 3D ; Fisher test P , 0.001). The evoked Ca 2+ transients (systolic) in PGC1b 2/2 myocytes were of larger amplitude (F/F 0 ¼ 1.96 + 0.082, n ¼ 24, for WT vs. 2.47 + 0.13, n ¼ 34, for PGC1b 2/2 ; P , 0.01 ; Figure 3E ) and showed increased rates of rise (49.63 + 4.3/s, n ¼ 24 in WT vs. 90.98 + 8.85 /s, n ¼ 34 in PGC1b 2/2 ; P , 0.01; Figure 3F ).
Abnormal Ca 2+ homeostasis results from either increased Ca 2+ influx due to increases in L-type Ca 2+ currents or increased Ca 2+ release through sarcoplasmic reticular ryanodine receptors (RyR2) during AP firing. Peak Ca 2+ current amplitudes, which provide a direct measurement of Ca 2+ influx through L-type Ca 2+ channels, were not significantly different between WT and PGC1b 2/2 myocytes at 0 mV (WT, 214.45 + 0.85 pA/pF, n ¼ 7; PGC1b 2/2 , 13.4 + 1.02 pA/pF, n ¼ 8; P . 0.05; Figure 4A ). Thus, current-voltage relationships were similar in WT and PGC1b 2/2 ( Figure 4B) . However, Ca 2+ currents following a double-pulse protocol showed negative shifts in inactivation characteristics ( Figure 4C ; current traces at test potentials of 215, 220 and 225 mV). Figure 4D thus shows that the half-voltage of activation (V1 2 of activation) shifted from 213.6 + 0.3 mV in WT to 29.6 + 0.7 mV in PGC1b 2/2 . Likewise, the half-voltage of inactivation (V1 2 of inactivation) shifted from 224.9 + 0.2 mV in WT to 219.7 + 0.2 mV in PGC1b 2/2 . This led to a small increase in window current ( Figure 4D, inset) . Consistent with arrhythmogenic Ca 2+ homeostasis in PGC1b 2/2 , qPCR showed increased expression of Ca 2+ /calmodulin-dependent protein kinase II (CAMKII), RyR2, and skeletal muscle type calsequestrin (CASQ1), despite maintaining similar levels of CACNA1C (cardiac L-type Ca 2+ channel) expression ( Figure 4E ).
PGC1b 2/2 myocytes show abnormal excitability
Surface areas of ventricular myocytes, measured by whole-cell capacitance, were similar in WT and PGC1b 2/2 ( Figure 5A ; 146 + 10 pF in WT, 143 + 9 pF in PGC1b 2/2 ; P . 0.05, n ¼ 18 each), consistent with the observed lack of hypertrophic cardiac myopathy. Most PGC1b 2/2 myocytes (10 of 15 cells) showed oscillatory episodes, indicating instabilities in the resting membrane potential ( Figure 5B , lower trace), in contrast to stable resting membrane potentials in WT ( Figure 5B, upper trace) . These resting membrane potential oscillations in PGC1b 2/2 were not mediated by increases in diastolic Ca 2+ , as the 5 mM BAPTA present in the pipette solution would have chelated any Ca 2+ increase. PGC1b 2/2 myocytes showed hyperpolarized resting potentials ( Figure 5C ; 284 + 1 mV, n ¼ 14 in WT vs. 291 + 1 mV in PGC1b 2/2 ; P , 0.001, n ¼ 15). These were not atributable to intracellular ATP depletion opening K ATP channels, because the 5 mM ATP in the pipette saline should have effectively closed the K ATP channels. Interestingly, the excitability of PGC1b 2/2 myocytes was enhanced, in contrast to the loss of excitability expected from the hyperpolarized resting potentials.
APs were triggered more readily in PGC1b 2/2 myocytes than WT. APs could be triggered by 500 pA (2 ms duration) current injection in eight of 15 PGC1b 2/2 myocytes, whereas .1000 pA (2 ms duration) current injections were required to generate APs in all WT myocytes studied. APs in WT myocytes had a triangular waveform, with no evidence of EADs and delayed after-depolarizations (DADs; 140 action potentials from 14 cells; Figure 5D ). In contrast, APs recorded from PGC1b 2/2 myocytes ( Figure 5E ) showed both EADs and DADs (Figure 5E, inset) . Such DADs were of small amplitude and did not share the usual cycles of waxing and waning amplitudes typical of classical DADs associated with diastolic Ca 2+ release. This could reflect chelation of intracellular Ca 2+ by inclusion of 5 mM BAPTA in the patch-clamp recording pipettes. Oscillatory resting membrane potentials, EADs, and DADs induce arrhythmia in whole hearts. 33 APs recorded from PGC1b 2/2 myocytes ( Figure 5F , left panel, top trace) showed significantly larger amplitudes (114 mV in WT vs. 119 mV PGC1b deletion induces cardiac arrhythmia in PGC1b 2/2 ) and increased rates of rise (639 + 39 V/s, n ¼ 15 in PGC1b 2/2 vs. 463 + 39 V/s, n ¼ 14 in WT; P , 0.01). The latter are represented as negative derivatives of AP traces ( Figure 5F , left panel, lower traces). They reflect the time course of Na + channel opening during the AP upstrokes and suggest an increase in maximum Na + current (P , 0.01) during such upstrokes ( Figure 5F , right). The underlying increase in Na + conductance could result not only from increased cardiac Na + channel expression, suggested by increased SCN5A mRNA in the qPCR study ( Figure 5G ), but could also arise from an increased Na + channel availability, resulting from altered resting or take-off membrane potentials, as well as modulation by increased levels of lysophosphatidylcholine.
PGC1b 2/2 myocytes show increased K 1 conductance
PGC1b 2/2 myocytes showed greater transient outward K + currents, which constitute the major repolarizing current in mouse myocytes ( Figure 6A ; 40-80 mV, P , 0.05). They also showed a greater average amplitude of sustained K + currents at different voltages ( Figure 6A) , as well as significantly increased inward rectifying current ( Figure 6B) , which may be responsible for their more hyperpolarized resting potentials. Of the 36 K + channel transcripts identified by microarray analysis, only Kcna5 was significantly increased, a finding further confirmed by qPCR ( Figure 6C) . The increased transient outward K + currents in PGC1b 2/2 hearts might be associated with Kv1.5 currents encoded by Kcna5.
Opening of multiple subtypes of voltage-gated and inwardly rectifying K + channels during APs normally contribute sufficient repolarization reserve to prevent EADs and DADs, maintaining stable diastolic resting membrane potentials. 34 However, the electrophysiological changes observed here together reduced electrophysiological stability in PGC1b 2/2 . Thus, when step currents of varying amplitudes (50 -500 pA) and duration (250 -3000 ms) were applied, WT myocytes responded, as expected, with a single action potential followed by a prolonged plateau phase, but failed to induce multiple action potentials ( Figure 6D) . In contrast, PGC1b 2/2 myocytes responded with a burst firing of multiple action potentials at the onset of the current step, which slowly subsided and regenerated ( Figure 6D, right panel) . This neurone-like behaviour of burst firing in cardiac cells is very rare in ventricular myocytes, and might cause abnormal automaticity and an enhanced susceptibility to ventricular tachycardia and fibrillation.
Discussion
PGC1b is involved in regulation of mitochondrial biogenesis and energy homeostasis, impairments in which are associated with the metabolic conditions of obesity, insulin resistance, and type 2 diabetes. PGC1b plays a major role in controlling basal mitochondrial function, and also participates in tissue-specific adaptive responses during metabolic stress. 17, 18, 21 PGC1b knockout has been associated with reduced mitochondrial volume fractions in both cardiac and soleus muscles, 21 and reduced state 3 respiration rates 18 and ATP production in soleus muscle, 21 and altered circadian rhythms. 17 Using the murine PGC1b as a model, we demonstrate here that deletion of this metabolic transcriptional coactivator induces major changes in cardiac energy and lipid homeostasis, revealed by transcriptomic and lipidomic methods. Our previous studies had indicated that expression levels of the complementary PGC1a would not have been altered in cardiac tissue, 21 in which the present paper provides the first report of the cardiac electrophysiological effects of altering PPAR pathways. These were further accompanied by altered Ca 2+ homeostasis and electrophysiological abnormalities at the myocyte level, and increased ventricular arrhythmogenicity particularly during adrenergic stress.
Transcriptomic analysis thus demonstrated a down-regulation of genes related to the electron transport chain, oxidative phosphorylation, and the Krebs cycle. There were accompanying increases in expression of genes related to cardiac hypertrophy (ATF3, IFRD1, TNNT1, TNNI2, ACTA1, NEB, MYL1, and MAP3K6), hypoxia, and heart failure (FKPB5, ZBTB16, SERPINE1, CTGF, TSC22D3, KLF2, HSPA1A, and HSPA1B), despite an absence of phenotypic signs of cardiac hypertrophy, ischaemia, or heart failure. 17, 18, 21, 35 There was also an up-regulation of cardiac stress-related cAMP, b-adrenergic signalling, Ca 2+ signalling, and glucocorticoid receptor signalling pathways. Such changes would be expected to reflect impairments in the corresponding bio-energetic and signalling pathways.
Lipidomic analysis then demonstrated an accumulation of the lipotoxic lysophosphatidylcholine, known to exert pro-inflammatory and pro-arrhythmogenic effects. Such accumulation is often associated with impaired mitochondrial function in cardiac tissue. 27, 36, 37 It often occurs along with severe cardiac hypoxia and ischaemia, 28 in metabolic diseases including overt diabetes and advanced atherosclerosis, 30 and in inflammatory diseases such as asthma. 30, 38 The arrhythmogenic effects of lysophosphatidylcholine have previously been extensively studied at both the cellular and the whole-heart levels. 29,39 -41 Thus, lysophosphatidylcholine has been shown to increase K + and Ca 2+ conductances, 41 slow inactivation of voltagegated Na + channels, 42, 43 and increase their opening at the resting membrane potential. 44 They also induce EADs, DADs, 29, 41 and abnormal intracellular Ca 2+ transients, 41 alter cellular levels of cAMP, 39 and induce cardiac arrhythmia. 29, 40 All these factors are associated with ventricular arrhythmia during cardiac ischaemia and hypoxia. 28, 45, 46 The observed increases in cardiac lysophosphatidylcholine in PGC1b 2/2 mice could therefore contribute to the increased risks of arrhythmia and sudden cardiac death 4, 5, 47 among individuals suffering from obesity, diabetes, and insulin resistance. 1 -3 Our electrophysiological studies then demonstrated, for the first time, that PGC1b deletion leads to cardiac arrhythmogenicity, whether assessed during isoprenaline challenge in vivo or during PES in Langendorff-perfused hearts. These were accompanied by a wide range of electrophysiological changes; each in themselves bear upon the presence or absence of arrhythmogenic tendency. These involved alterations in Ca 2+ homeostasis, reflected in our observations of abnormal Ca 2+ transients. This could arise either from increase in Ca 2+ influx due to delayed inactivation of L-type Ca 2+ current ( Figure 4A and B) or increase in release of Ca 2+ from sarcoplasmic reticulum due to increased expression of RyR2 and CAMKII and Casq1, all of which have been known to be involved in Ca 2+ release from intracellular Ca 2+ stores. In the context of the emerging role of intracellular stores in isoprenaline-induced ventricular arrhythmia in CPVT models, 48 the characterization of the precise role of intracellular Ca 2+ stores in arrhythmogenesis of PGC1b 2/2 mice could be an important direction to pursue in future studies. There was an increased Na + channel excitability, resulting in a myocyte hyperexcitability and increased rate of rise of AP waveforms. Alterations in K + channel properties took the form of increased K + conductances and hyperpolarized resting membrane potentials. Finally, membrane potential instabilities appeared both as oscillations in resting potentials and as EADs and DADs. The EADs occurred in the 220 to 240 mV range, coincident with the increased window currents shown by L-type Ca 2+ channels, away from voltages showing the increased K + conductances. Furthermore, the EADs and DADs persisted despite correction of Ca 2+ homeostasis by buffering intracellular Ca 2+ , consistent with their generation primarily by a Ca 2+ influx. There were also episodes of burst firing of action potentials. Changes of this kind resembled phenomena previously observed following administration of exogenous lysophophatidylcholine to WT ventricular myocytes. 29, 44 Together, they could well converge to produce the observed arrhythmic PGC1b 2/2 phenotype.
We thus implicate the metabolic transcriptional coactivator PGC1b, known to be involved in mitochondrial biogenesis and energy metabolism, in a range of changes involving altered cardiac energetics, cardiac lipotoxicity, and electrophysiological changes, converging to an arrhythmic phenotype. This could contribute to the increased cardiac mortality in multifactorial metabolic diseases, including obesity, diabetes, and insulin resistance. PGC1b deletion thus produces transcriptomic changes, leading to increased Na + and K + channel, RyR2, and calsequestrin expression. These are in addition to impaired mitochondrial biogenesis and energetics reducing ATP production. These could together potentially themselves lead to arrhythmic consequences. In addition, there is an increased lysophosphatidylcholine accumulation. Lysophosphatidylcholine itself is also known to exert arrhythmogenic effects, and would then do so against this already altered electrophysiological background. These factors could thus together lead to the observed abnormal excitability and Ca 2+ homeostasis associated with the demonstrated arrhythmic phenotype. Any therapeutic management of these changes would therefore require targeting of the primary upstream PGC1b abnormality rather than its multiple downstream consequences.
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